Tarextumab
Tarextumab
Tarextumab (pronounced: ta-rex-tu-mab) is a monoclonal antibody designed for the treatment of cancer. It was developed by Oncomed Pharmaceuticals and is also known as OMP-59R5.
Etymology
The name 'Tarextumab' follows the World Health Organization's guidelines for the nomenclature of monoclonal antibodies, where '-mab' signifies it is a monoclonal antibody, 'tu' indicates it targets tumors, and 'rex' is a unique stem used for the specific antibody.
Mechanism of Action
Tarextumab works by targeting and inhibiting the Notch signaling pathway, a system involved in cell communication that plays a crucial role in cell development and differentiation. In many cancers, this pathway is overactive, leading to uncontrolled cell growth and tumor formation. By inhibiting this pathway, Tarextumab can slow or stop the growth of cancer cells.
Clinical Trials
Tarextumab has undergone several clinical trials for various types of cancer, including pancreatic cancer, small cell lung cancer, and neuroendocrine tumors. However, as of 2016, Oncomed Pharmaceuticals announced that it would not continue the development of Tarextumab due to insufficient efficacy in phase 2 trials.
Related Terms
- Monoclonal antibody
- Notch signaling pathway
- Clinical trial
- Pancreatic cancer
- Small cell lung cancer
- Neuroendocrine tumor
External links
- Medical encyclopedia article on Tarextumab
- Wikipedia's article - Tarextumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski